Oct 16, 2019 The most influential scientific research consortium of its kind: 37 biopharmaceutical companies work in a pre-competitive environment to advance PBPK modeling and simulation, progress new drug and biologics research, create new regulatory frontiers, foster ongoing modeling and simulation education, and present industry awards
Certara Launches BaseCase Data Studio, Enabling Pharma and MedTech Clients to Conduct Advanced Data Analyses During Value-based Product Discussions
Oct 1, 2019BaseCase platform can now perform live statistical modeling and sophisticated data analyses, delivering evidence-based claims to support value messages during payer, provider and HCP discussions
FDA Renews Licenses for Synchrogenix’s GlobalSubmit Software to Review and Validate New Drug and Biologics Applications
Leveraged since 2005, 6,000+ FDA reviewers are now using GlobalSubmit technology
Certara Introduces Hasharc Decentralized Application for Healthcare at Hedera Hashgraph Open Access Launch
New Certara DApp provides transaction insights on Hedera network and supports data provenance for supply chain uses cases, improving transparency and disclosure for healthcare clients
Certara Launches Version 8.2 of its Industry-leading Phoenix PK/PD Modeling and Simulation Software for Drug Development
Aligned with newly issued FDA Draft Guidance, Phoenix supports electronic data, methods and results audit, traceability and communication requirements.
Data Manager allows clients to include large, real-world datasets in their customer presentations in an efficient, compliant manner
The ability to analyze and visualize sequence-activity relationships in proteins and peptides added to D360’s biologics toolkit for drug discovery research
The strategic expansion of Certara’s US Access practice provides clients with opportunities to confront increasing drug pricing and reimbursement challenges
PRINCETON, NJ – July 9, 2019 – Certara has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide.
Certara Announces First Recipients of Certara-Monash University Industry Drug Development Fellowships
PRINCETON, NJ – June 25, 2019 – Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, and Monash University today announced the recipients of the inaugural Certara-Monash University Industry Drug Development Fellowships – Dr. Katrina Hui, Dr. Yu-Wei Lin, and Dr. Zheng Liu.